Scarica l'app Stockscreener
27.19
1.45%
-0.40
Dopo l'orario di chiusura:
27.19
Pharvaris Nv Borsa (PHVS) Ultime notizie
What’s the fair value of Pharvaris N.V. stockPortfolio Return Summary & Expert Verified Movement Alerts - mfd.ru
Aug Spikes: What is the earnings history of Pharvaris NVPortfolio Profit Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Analysts Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $40.56 - Defense World
Precision Trading with Pharvaris N.v. (PHVS) Risk Zones - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Analysis: Navigating A 65% Upside In Biotech Innovations - directorstalkinterviews.com
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Surprises Report: Can Pharvaris NV stock outperform in a bear marketPrice Action & Expert-Curated Trade Recommendations - baoquankhu1.vn
Layoff Watch: Is Box Inc. a speculative investmentWeekly Market Outlook & Short-Term High Return Ideas - baoquankhu1.vn
Insider Buy: How correlated is Pharvaris NV to the S P500July 2025 Final Week & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap - Yahoo Finance
Technical Reactions to PHVS Trends in Macro Strategies - Stock Traders Daily
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts - The Globe and Mail
Pharvaris N.V. (PHVS) Stock Analysis: A Promising 83% Upside Potential Amid Biotech Advancements - DirectorsTalk Interviews
Why Pharvaris N.V. stock attracts high net worth investorsMarket Rally & Reliable Price Breakout Signals - Улправда
Why Pharvaris N.V. stock remains a top recommendationOil Prices & Real-Time Market Sentiment Reports - ulpravda.ru
Will Pharvaris N.V. (9EN) stock split increase liquidity2025 Year in Review & Capital Efficient Trade Techniques - Улправда
Street Watch: Why Pharvaris N.V. stock remains a top recommendationDay Trade & Daily Entry Point Trade Alerts - Улправда
How Pharvaris N.V. (9EN) stock reacts to fiscal policiesJuly 2025 PreEarnings & Low Volatility Stock Suggestions - Улправда
How Pharvaris N.V. stock responds to policy changes2025 Market Outlook & Real-Time Volume Trigger Notifications - Улправда
Pharvaris (NASDAQ:PHVS) Shares Up 9.1%Still a Buy? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
What analysts say about Pharvaris NV stockInstitutional Buying Trends & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
LongTerm Outlook Is Uravi Defence and Technology Limited a BuyandHold StockEarnings Volatility Patterns & Low Cost Stock Ideas - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris N.V. (PHVS) Stock Analysis: Assessing a 66.61% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris (NASDAQ:PHVS) Shares Up 3.8%Should You Buy? - MarketBeat
Aug Retail: How Pharvaris NV stock responds to policy changesJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - moha.gov.vn
Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 6.9%Time to Sell? - MarketBeat
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans - Sahm
Behavioral Patterns of PHVS and Institutional Flows - Stock Traders Daily
Pharvaris N.V.(NasdaqGS: PHVS) added to NASDAQ Biotechnology Index - marketscreener.com
What Does Wall Street Think About Pharvaris N.V. (PHVS)? - Insider Monkey
Sentiment Recap: Is Pharvaris NV 9EN stock at risk of policy regulationQuarterly Growth Report & Consistent Return Investment Signals - moha.gov.vn
Why analysts upgrade Pharvaris N.V. stockJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
Is Pharvaris N.V. stock trading near support levelsWeekly Volume Report & Risk Managed Investment Signals - DonanımHaber
Aug Final Week: Why analysts upgrade Pharvaris N.V. stockExit Point & Reliable Entry Point Trade Alerts - Улправда
Is Pharvaris N.V. (9EN) stock a momentum leaderJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
How geopolitical tensions affect Pharvaris N.V. stockJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Total debt per share of Pharvaris N.V. – MUN:9EN - TradingView — Track All Markets
New Highs: How Pharvaris NV stock responds to policy changesWeekly Risk Summary & Reliable Intraday Trade Plans - moha.gov.vn
Pharvaris (PHVS) Is Down 5.7% After Pivotal RAPIDe-3 Deucrictibant Data And 2026 Filing Plan - Sahm
Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen - Defense World
Pharvaris N.V. $PHVS Shares Bought by TFG Asset Management GP Ltd - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2025-12-09 - Seeking Alpha
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - AOL.com
Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial - HCPLive
Pharvaris stock gains on HAE drug meeting late-stage study goals - MSN
GENERAL ATLANTIC, L.P.'s Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema - Sahm
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):